Momentum: Crinetics' Acromegaly Study Data and Tesla's Morgan Stanley Boost
- September 11th, 2023
- 652 views
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) has reported promising results from its Phase 3 PATHFNDR-1 study evaluating paltusotine, an oral once-daily investigational compound designed for acromegaly treatment. The study achieved its primary endpoint and all secondary endpoints. Notably, 83% of participants treated with paltusotine maintained normal insulin-like growth factor 1 (IGF-1) levels, compared to just 4% on placebo.
$CRNX was trading at $28.39 in pre-market, marking a notable increase of $12.42 (+77.77%)
In other news, Morgan Stanley has upgraded Tesla, Inc. (Nasdaq: TSLA) from Equal-Weight to Overweight and simultaneously increased the price target from $250 to $400.
Considering that $TSLA closed at $248.50 on Friday, this updated price target suggests a potential upside of $151.50 or approximately 60.95%, based on the global financial services firm's analysis
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
DOT, DoW, DHS Join Forces to Protect Southern Border Airspace
October 16th, 2026FTC Sues Ticket Broker Over Unlawful Tactics Used to Buy Millions of Tickets to Popular Live Events
October 15th, 2026October 15th, 2026FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer
October 14th, 2026U.S. Treasury Announces Record Enforcement Actions Against Bank of America
October 14th, 2026
Member Login